January 27th 2024, 8:00pm
Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.
January 27th 2024, 6:00pm
Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.
January 27th 2024, 2:00pm
Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.
January 26th 2024, 10:00pm
Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.
January 26th 2024, 8:00pm
Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.
January 26th 2024, 2:00pm
Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.
January 25th 2024, 10:00pm
Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.
January 24th 2024, 10:00pm
ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.
January 23rd 2024, 11:00pm
ASCO Gastrointestinal Cancers Symposium
Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.
January 23rd 2024, 10:00pm
ASCO Gastrointestinal Cancers Symposium
Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.